Sign in →

Test Code NGSFX Reanalysis of Acute Myeloid Leukemia 4- or 11- Gene Panels, Additional Genes


Specimen Required


No additional specimen is required. This is a bioinformatics review of additional gene regions not analyzed in the previously ordered NGAMT / MayoComplete Acute Myeloid Leukemia, Therapeutic Gene Mutation Panel (FLT3, IDH1, IDH2, TP53), Next-Generation Sequencing, Varies or NGAML / MayoComplete Acute Myeloid Leukemia, 11-Gene Panel, Varies. Call 800-533-1710 for assistance with ordering.


Forms

1. Hematopathology Patient Information (T676)

2. If not ordering electronically, complete, print, and send an Hematopathology/Cytogenetics Test Request (T726) with the specimen.

Testing Algorithm

Only orderable as a reflex. Reflex testing is available upon request within 6 months of original NGAMT / MayoComplete Acute Myeloid Leukemia, Therapeutic Gene Mutation Panel (FLT3, IDH1, IDH2, TP53), Next Generation Sequencing, Varies or NGAML / MayoComplete Acute Myeloid Leukemia, 11-Gene Panel, Varies sample submission.

 

This is a bioinformatics and variant review only for the added gene regions.

 

For a list of genes and exons targeted by this test see Targeted Genes Interrogated by Myeloid Neoplasms, Comprehensive OncoHeme Next-Generation Sequencing.

Method Name

Only orderable as a reflex. For more information see:

-NGAMT / MayoComplete Acute Myeloid Leukemia, Therapeutic Gene Mutation Panel (FLT3, IDH1, IDH2, TP53) Next-Generation Sequencing, Varies

-NGAML / MayoComplete Acute Myeloid Leukemia, 11-Gene Panel, Varies

 

Next-Generation Sequencing (NGS)

Specimen Type

Varies

Specimen Stability Information

Specimen Type Temperature Time
Varies Varies 14 days

Clinical Information

Next-generation sequencing is a comprehensive molecular diagnostic methodology that can interrogate multiple regions of genomic tumor DNA in a single assay. Many hematologic neoplasms are characterized by morphologic or phenotypic similarities but can have characteristic somatic mutations in many genes that enable more specific categorization. In addition, many myeloid neoplasms lack a clonal cytogenetic finding at diagnosis (normal karyotype) but can be diagnosed or confirmed and classified according to the gene mutation profile. Patients with unexplained cytopenias may harbor acquired genetic alterations in hematopoietic cells (clonal cytopenias of uncertain significance), which may carry the risk of developing overt myeloid malignancies. The presence and pattern of gene mutations in known or suspected myeloid neoplasm can provide critical diagnostic, prognostic, and therapeutic information to help guide management for the patient’s physician.

Reference Values

Only orderable as a reflex. For more information see:

-NGAMT / MayoComplete Acute Myeloid Leukemia, Therapeutic Gene Mutation Panel (FLT3, IDH1, IDH2, TP53), Next-Generation Sequencing, Varies

-NGAML / MayoComplete Acute Myeloid Leukemia, 11-Gene Panel, Varies

Day(s) Performed

Monday through Friday

Report Available

16 to 21 days

Performing Laboratory

Mayo Clinic Laboratories in Rochester

CPT Code Information

81450